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ABSTRACT OF THE THESIS 
 
Lipid-Polymer hybrid nanoparticles: photoacoustic imaging platform applied to ovarian 
cancer diagnosis 
 
by 
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University of California, San Diego, 2017 
 
Professor Jesse Jokerst, Chair 
Professor Sheng Zhong, Co-Chair 
 
 
The survival rate of patients with ovarian cancer is over 90% in Stages I and II but 
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detection strategies based on CA125 testing are ineffective. Hence, this screening 
approach not only fails to decrease ovarian cancer mortality but also causes significant 
harm including major surgery in cancer free women. Fortunately, the metrics of 
ultrasound-based techniques are encouraging—a recent large scale trial of over 200,000 
women indicated that the sensitivity and specificity were 89.4% and 99.8%, respectively, 
when combined with CA125 tests. However, the positive predictive value of ovarian 
cancer was only 43.3%. Therefore, we hypothesize that using photoacoustic ultrasound 
combined with lipid-polymer hybrid nanoparticles can achieve advances in specificity 
and sensitivity that are need in population-wide studies. In our study, we used poly-lactic-
co-glutamic acid (PLGA), lecithin, and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[folate(polyethylene glycol)]-5000 (DSPE-PEG-folate) to 
fabricate hybrid nanoparticles. The photoacoustic imaging agents DiR or IR-1061 were 
encapsulated in PLGA hydrophobic core. The folate-functionalized nanoparticles can 
actively target HeLa cells which overexpress folate receptors on their cell membrane. The 
main hypothesis is that the folate-functionalized nanoparticles could produce higher 
contrast between ovarian cancer tissues and normal tissues than nanoparticles without 
folate modification. Also, we proved our IR-1061-loaded nanoparticles had a pH-
responsive release profile. We can even use photoacoustic imaging to track the releasing 
IR-1061 in PBS at different pH values. In the future, we attempt to conjugate IR-1061 
molecules with anti-cancer drugs to endow our nanoparticles theranostic capability. Our 
long-term goal is to achieve in vivo photoacoustic imaging and theranostic treatment of 
ovarian cancer patients. 
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Introduction 
1. Tools of early ovarian cancer diagnosis 
Ovarian cancer is highly curable in the first and second stage but it is rather lethal 
in the late stages. It is indicated that the 5-year survival rate is over 90% if the patients 
are diagnosed in early stages (stage I and stage II). 3 
However, traditional CA125 testing is not effective for screening potential 
patients with ovarian cancer and results in less than 50% of 5-year survival rate3, 4. 
Moreover, this screening method has been evaluated as D grade5 by US Preventive Task 
Force recently. Fortunately, this screening method is improved when it is combined with 
ultrasound imaging. Recently, a research group in UK has performed UKCTOCS trial on 
more than 200,000 female patients using CA125 testing combined with ultrasound 
imaging and it showed that the sensitivity and specificity can reach 89.4% and 99.8%6, 
respectively.  Although CA125 testing combined with ultrasound imaging has promising 
sensitivity and specificity, the positive predictive value of this method is only 43.3%. The 
main reason of diagnosis failure is due to the weak contrast between malign tumor tissues 
and healthy tissues. This research study aims to use photoacoustic ultrasound and 
molecular imaging to overcome this problem.  
Different from traditional ultrasound imaging, photoacoustic imaging utilize 
imaging agents accumulated in tumor tissues to create photoacoustic signals after laser 
irradiation. Briefly, the photoacoustic imaging agents accumulated in biological tissues 
absorb the laser irradiation energy and undergo thermos-elastic expansion. Then, the
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 thermo-elastic expansion creates pressure wave in biological tissues. The pressure wave 
signal is itself a sound wave signal and could be received by ultrasound transducer. So, 
it’s a “light in” and “sound out” imaging modality. Compared to traditional ultrasound 
imaging, photoacoustic imaging could enhance the contrast between tumor tissues and 
normal tissues.   
 
2. Molecular imaging of folate receptors on ovarian cancer cells 
     We make use of molecular imaging to specifically image ovarian cancer cells via 
over-expressed folate receptors on ovarian cancer cell membrane. However, the biggest 
limit to combine photoacoustic and molecular imaging is the lack of appropriate imaging 
agents. For example, microbubbles demonstrate strong ultrasound imaging when they 
actively target to endothelial cells in vasculature. Nonetheless, microbubbles suffer from 
short half-time and their large sizes prevent them from passing blood vessels and 
targeting the folate receptors on ovarian cancer cells1, 7. Hence, in this study, we 
developed dye-loaded nanoparticles as photoacoustic imaging agents. Other research 
groups have developed a series of nanoparticle-based imaging agents8-12 applied to 
ultrasound imaging to overcome the disadvantages of microbubbles used in ovarian 
cancer in vivo imaging1, 2.  
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3. Photoacoustic imaging agents 
     Light and imaging fluorophores have been profoundly used in clinical practice 
and scientific research13, 14. Since photoacoustic imaging relies on laser irradiation to 
produce signals, proper usage of light and fluorophores is critical. To promote the 
practical use in in vivo biomedical imaging, near-infrared I (NIR I, 750-900 nm) and 
near-infrared II (NIR II, 1000-1700 nm) fluorophores are selected because of less auto-
fluorescence disturbance, deep tissue penetration, and less photon scattering14-18.  
 
Figure 1: Chemical structure of photoacoustic imaging agents. (a) DiR (b) IR-1061. 
 
     In this study, we select DiR and IR-1061 as our photoacoustic imaging agents. 
DiR has absorbance peak at 765 nm while IR-1061 has absorbance peak at 1074 nm.  So, 
both imaging agents are either NIR fluorophores. DiR is a hydrophobic fluorophore and 
has longer fluorescence lifetime than other hydrophilic fluorophores Cy5 and Cy719 and 
high quantum yield. It has been successfully applied to improved fluorescence in vivo 
imaging19. The hydrophobic property of DiR make it compatible to our lipid-polymer 
hybrid nanoparticles and could give rise to higher loading efficiency. Similarly, IR-1061 
is hydrophobic and could also lead to high dye loading efficiency. Moreover, IR-PEG 
nanoparticles loaded with IR-1061 has been developed by another research group. This 
(a) (b) 
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IR-PEG nanoparticle successfully provided enhanced resolution in in vivo fluorescence 
imaging in mice because of its’ longer emission wavelength over 1000 nm20. However, 
the quantum yield of IR-1061 is only 1.8%, which causes low fluorescence intensity and 
hinders its’ further use in biological imaging of deeper tissues. Although the low quantum 
yield of IR-1061 lowers down the signal intensity in fluorescence imaging, it may convert 
more laser irradiation energy to heat, which promotes thermos-elastic expansion in 
biological tissues and improves photoacoustic signals.     
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Results 
1. Spectral Properties of free DiR and IR-1061: 
     The absorbance spectra of DiR molecules dissolved in acetonitrile was shown in 
Figure 2 (a). It showed an absorbance peak at 765 nm. Also, the absorbance of DiR 
illustrated a concentration-dependent increasing tendency. The absorbance of DiR at 
different concentrations were taken to do a linear regression and obtained a standard line. 
It turns out that the DiR concentrations and the absorbance show remarkably linear 
tendency with R2>0.99 (Figure 2 (b)). We used this standard line combined with the 
absorbance of destroyed DiR-loaded hybrid nanoparticles to quantify the loading 
efficiency of DiR. 
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Figure 2: Spectral properties of DiR (a) UV/Vis absorbance spectra (500-850 nm) of 
free DiR molecules in acetonitrile at different concentrations. (b) Standard line of free 
DiR molecules in acetonitrile at 765 nm. 
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     Similarly, IR-1061 molecules were dissolved in DMSO and the absorbance 
spectra were obtained by using UV/Vis/NIR spectrophotometer. Free IR-1061 in DMSO 
showed a pronounced absorbance peak at 1074 nm with a shoulder peak at 945 nm 
(Figure 3 (a)). We used the absorbance of IR-1061 at 945 nm and 1074 nm to obtain the 
standard lines. It illustrated that the standard line at either wavelength have remarkable 
linear tendency with R2> 0.999 (Figure 3 (b)). The standard line at 1074 nm was used to 
quantify the encapsulated IR-1061 in hybrid nanoparticles after the nanoparticles were 
destroyed with DMSO.   
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Figure 3: Spectral properties of IR-1061. (a) UV/Vis/NIR absorbance spectra (600-
1500 nm) of free IR-1061 molecules in DMSO at different concentrations. (b) Standard 
line of free IR-1061 molecules in DMSO at 945 and 1074 nm. 
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2. Characterization of Nanoparticles 
(1) DiR-loaded hybrid nanoparticles: 
Scheme 1: Schematic diagram of DSPE-PEG-FA and hybrid nanoparticles. (a) The 
chemical structure of DSPE-PEG-FA was demonstrated. The folate molecule was shown 
as red motif and PEG polymer was shown as black curl. The DSPE phospholipid was 
draw as green hydrophilic head and two black hydrophobic tails. (b)  The hybrid 
nanoparticles were made by nanoprecipitation method. 
 
     The DiR-loaded hybrid nanoparticles were prepared by nanoprecipitation method. 
As depicted in Scheme 1, the PLGA polymer matrix and DiR molecules formed 
hydrophobic cores and the hydrophobic tails of lecithin and DSPE-PEG-FA molecules 
were intercalated into the hydrophobic cores via hydrophobic interactions. Then, the 
hydrophilic heads of lecithin and DSPE-PEG-FA molecules formed hydrophilic shells to 
stabilize hybrid nanoparticles in aqueous phase.  Table 1 summarized the size, PDI, zeta-
potential, and loading efficiency of DiR. We compared the properties of hybrid 
nanoparticles without any cargos and PLGA nanoparticles. It illustrated in Figure 4 (a) 
that hybrid nanoparticles were one and a half times bigger than PLGA particles. This may 
be due to the additional lecithin and DSPE-PEG shell which enlarges the average size of 
DSPE-­‐PEG-­‐FA 
PLGA 
DiR	  
dye 
lecithin 
DSPE-­‐PEG-­‐
FA 
nanoprecipitation 
self-­‐assembly 
(b) (a) 
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hybrid nanoparticles. Also, after adding the lipid shell, the zeta-potential became slightly 
more positively charged (from -33.1 mV to -29.8 mV). This may be due to the fact that 
PEG layer moderately shells the negatively charged PLGA hydrophobic core. After DiR 
molecules were encapsulated into the hybrid nanoparticles, the average size of the hybrid 
nanoparticles become even bigger because of the extra DiR molecules loaded into the 
hydrophobic core. Similarly, folate-functionalized nanoparticles had the largest average 
size which is due to the additional folate layer.  Also, we found the size distribution of 
DiR-loaded nanoparticles with or without folate were similar except a second peak in the 
folate-functionalized nanoparticles with DiR (Figure 4(b)). The second peak may result 
from slightly aggregation of folate-functionalized nanoparticles with DiR and higher up 
the value of average size. After DiR-loaded hybrid nanoparticles were destroyed by 
acetonitrile, the absorbance was measured. Combined with the DiR standard line (Figure 
2 (b)), we obtained the loading efficiency of hybrid nanoparticles with and without folate 
modification was 74.8% and 70.1%, respectively. The loading efficiency of the hybrid 
nanoparticles is so high. This may because the lipid monolayer at the interface of PLGA 
hydrophobic core prevents DiR molecules from diffusing out of nanoparticles21. 
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Table 1: Characterization of hybrid nanoparticles and PLGA nanoparticles. The 
average size, PDI, and zeta-potential of hybrid NP w/DiR/FA, hybrid NP w/DiR, hybrid 
NP w/o DiR, and PLGA NP were measured by DLS. The loading efficiency of all 
samples was calculated using standard line in Figure 2 (b).  
 
sample Average 
size (nm) 
PDI Zeta-potential 
(mV) 
Loading 
efficiency (%) 
Hybrid NP 
w/DiR/FA 
211.8±42.8 0.233 -26.0±6.6 74.8±11.9 
Hybrid NP w/DiR 174.5±12.5 0.151 -29.0±3.2 70.1±6.8 
Hybrid NP w/o 
DiR 
65.8±0.3 0.425 -29.8 / 
PLGA NP 45.7±0.5 0.187 -33.1 / 
12 
	  
	  
	  
 
 
Figure 4: Size distribution of DiR-loaded hybrid nanoparticles and PLGA 
nanoparticles. PLGA NP, hybrid NP, hybrid NP w/DiR, and hybrid NP w/DiR/FA were 
prepared by nanoprecipitation method. The size distribution of all samples was examined 
by DLS. 
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(2) IR-1061-loaded hybrid nanoparticles: 
     We prepared the nanoparticles by a modified nanoprecipitation method20. The 
effect of different weight ratio of PLGA and IR-161 was studied.  Table 2 and Table 3 
summarize the size, PDI, zeta-potential, and loading efficiency of IR-1061 of 
nanoparticles with PLGA weight ratio of 05 and 10, respectively. We found that the 
nanoparticles with higher weight ratio of PLGA generally have larger size. For example, 
the nanoparticles with PLGA weight ratio of 05 often have the size around 110 nm while 
those with PLGA weight ratio of 10 usually have the size over 120 nm. Also, it is 
indicated in Figure 5 (a) and (c) that the size of nanoparticles did not significantly 
increase if we higher up the weight ratio of IR-1061. However, the zeta-potential of the 
nanoparticles dramatically shifted from -36 mV to around -20 mV as shown in Figure 5 
(b) and (d).  The loading efficiency of IR-1061 remarkably increased with higher weight 
ratio of IR-1061. This may result from the hydrophobic and positively charged properties 
of IR-1061 molecules. It is well-known that PLGA core is hydrophobic and negatively 
charged. Hence, IR-1061 molecules could be trapped in the PLGA core via both 
hydrophobic interactions and electrostatic interactions.  Due to the bigger average size 
and higher loading efficiency of nanoparticles with weight ratio of PLGA/lipid/IR-1061 
as 10/20/3.0, we made use of this nanoparticle for the following cytotoxicity and release 
experiments. 
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Figure 5: Size and zeta-potential distribution of IR-1061-loaded hybrid 
nanoparticles. The IR-1061-loaded nanoparticles were prepared by nanoprecipitation 
method. The size distribution and zeta-potential were examined by DLS. 
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Table 2: Characterization of IR-1061-loaded hybrid nanoparticles with weight ratio 
of PLGA to lipid as 05 to 20. 
 
Table 3: Characterization of IR-1061-loaded polymeric liposome with weight ratio 
of PLGA to lipid as 10 to 20. 
      
Weight ratio of 
PLGA/lipid/IR-
1061 
Average 
size (nm) 
PDI Ζ-potential (mV) Loading 
Efficiency (%) 
05/20/0.1 106.2±1.3 0.215 -36.2±1.6 6.1 
05/20/0.2 113.0±1.4 0.208 -37.1±0.9 8.1 
05/20/0.5 114.6±1.7 0.199 -37.4±0.5 33.0 
05/20/1.0 110.9±1.4 0.201 -32.8±0.9 48.5 
05/20/2.0 116.9±0.2 0.246 -28.3±0.5 65.5 
05/20/3.0 106.3±0.7 0.262 -20.0±0.4 73.0 
Weight ratio of 
PLGA/lipid/IR-1061 
Average 
size (nm) 
PDI Ζ-potential (mV) Loading 
Efficiency (%) 
10/20/0.1 120.8±2.2 0.202 -36.1±1.5 6.2 
10/20/0.2 118.7±1.3 0.181 -37.0±0.5 10.6 
10/20/0.5 137.4±2.7 0.164 -36.0±1.0 19.7 
10/20/1.0 130.4±1.5 0.189 -34.9±0.5 32.4 
10/20/2.0 127.2±2.0 0.222 -29.8±0.5 59.1 
10/20/3.0 126.7±1.3 0.229 -23.8±0.8 67.8 
10/20/0.0 90.1±1.1 0.221 -41.9±1.2 0 
16 
	  
	  
	  
Figure 6 shows transmission electron microscopy of IR-1061-loaded hybrid 
nanoparticles with weight ratio of PLGA/lipid/IR-1061 as 10/20/3.0. In Figure 6 (a), we 
found the size of our nanoparticles were not homogeneous. For example, the small 
nanoparticles could be as small as 50 nm and the large ones could be around 150 nm. 
This gives rise to their higher PDI value (0.229) shown in Table 3. Even though the size 
of our nanoparticles were not ideally homogenous, the morphology of almost all 
nanoparticles was in sphere shape. Besides, the lipid-polymer interface was obviously 
sharp as shown in Figure 6 (b).
 
Figure 6: Transmission electron microscopy (TEM) image of IR-1061-loaded hybrid 
nanoparticles at different magnifications. (a) 4000X (b) 10000X. 
  
 
 
 
 
 
lipid 
polymer 
(a) (b) 
0.5	  μm 200	  nm 
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(3) Spectral properties of IR-1061-loaded hybrid nanoparticles: 
     The absorbance spectra of IR-1061-loaded hybrid nanoparticles was demonstrated 
in figure 6. It showed an absorbance peak at 900 nm and a shoulder peak at 1087 nm. The 
spectral properties of IR-1061 are dramatically different between in hybrid nanoparticles 
(Figure 7 (a)) and in DMSO (Figure 3(a) and Figure 7 (b)). As we can see, when IR-1061 
molecules are encapsulated into nanoparticles, the spectral property shows an obvious 
blue shift. This may results from the aggregation of IR-1061 molecules in the PLGA 
hydrophobic core. However, when the IR-1061-loaded nanoparticles were destroyed by 
DMSO, the absorbance spectral properties were restored (Figure 7 (b)). We also 
destroyed nanoparticles without loading any IR-1061 and no absorbance peak show in 
this group (10/20/0.0 in Figure 7 (b)). This result further confirm the absorbance peaks 
stem from IR-1061 molecules inside nanoparticles. Therefore, we expect that we can 
utilize the blue shift to monitor the release profile of anticancer drugs when IR-1061 
molecules are conjugated with anticancer drugs. Specifically, when the IR-1061-drug 
conjugates are encapsulated in nanoparticles, we observe a main absorbance peak at 900 
nm. After the IR-1061-drug conjugates are released, the absorbance peak should shift 
from 900 nm to 1074 nm. Also, when time goes on, higher amount of releasing IR-1061-
drug conjugates will lead to higher absorbance and stronger photoacoustic signals.      
 
18 
	  
	  
	  
 
Figure 7: Spectral properties of IR-1061-loaded hybrid nanoparticles. (a) 
UV/Vis/NIR absorbance spectra (600-1400 nm) of IR-1061-loaded hybrid nanoparticles 
in Millipore water. (b) UV/Vis/NIR absorbance spectra (600-1500 nm) of destroyed IR-
1061-loaded hybrid nanoparticles in DMSO. 
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3. Cell experiments 
(1) folate receptor on A549, HeLa, and SKOV3 cells: 
     To choose optimal cell lines to confirm the active targeting capability of our 
nanoparticles, we utilize anti-folate receptor antibodies to stain folate receptors on the 
cell membrane of A549, HeLa, Ov2008, and SKOV3 cells. The results are shown in 
Figure 8. It was obvious that A549 cells had deficient expression of folate receptors since 
the FITC intensity was only 1.1 times higher than its’ control group. In contrast, HeLa 
cells pronouncedly overexpressed folate receptors on their cell membrane because the 
FITC intensity was 7.1 times higher than its’ control group. Besides, our ovarian cancer 
cell lines, Ov2008 and SKOV3, only moderately overexpressed folate receptors. Their 
FITC intensity was only 1.4 and 1.7 times higher than their control group, respectively. 
Hence, we chose A549 and HeLa cells as our negative and positive cell lines, 
respectively, for folate receptor expression to ideally validate active targeting capability 
of our folate-functionalized hybrid nanoparticles with DiR.  
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Figure 8: Folate receptors on A549, HeLa, Ov2008, and SKOV3. We immune-stained 
folate receptor on (a) A549, (b) HeLa, (c) Ov2008, and (d) SKOV3 cells and used flow 
cytometer combined with FITC-channel to examine the fluorescent intensity of cancer 
cells. The x-axis represents the fluorescent intensity while y-axis represents cell counts. 
The red line in every panel represents cells stained without primary antibodies while blue 
line represents cells stained with primary antibodies. All cell lines were further stained 
with FITC-conjugated secondary antibodies. 
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
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(2) cell uptake 
     To validate the active targeting capability of folate-functionalized hybrid 
nanoparticles, we treated HeLa and A549 cells with folate-functionalized hybrid 
nanoparticles loaded with DiR. Also, we treat these two cell lines with DiR-loaded 
nanoparticles without folate modification to compare the results. We used flow cytometer 
combined with APC-Cy7 channel to detect the fluorescent intensity of DiR inside cells. 
In Figure 9, we can see either HeLa or A549 cells had very little amount cell uptake of  
DiR-loaded nanoparticles without folate modification because the fluorescent intensity 
was almost the same as the control groups. In contrast, both cell lines had a certain level 
of cell uptake of folate-functionalized nanoparticles loaded with DiR in 0.5 h (Figure 9 
(a)). To relatively quantify the cell uptake amount, 95% of HeLa cells engulfed a great 
amount of folate-functionalized nanoparticles while only 45% of A549 cells engulfed the 
same amount of the nanoparticles. If we prolonged the treatment time to 1h, almost all 
HeLa cells (97%) engulfed high amount of nanoparticles while only 49% of A549 cells 
engulfed the same amount of nanoparticles (Figure 9 (b)). These results confirm the 
active targeting capability of our folate-functionalized hybrid nanoparticles because HeLa 
cells which overexpressed folate receptors on their cell membrane had more cell uptake 
of these folate-functionalized nanoparticles than A549 cells which had deficient folate 
receptors. 
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Figure 9: Flow cytometry results of HeLa and A549 cells treated with NP w/DiR/FA 
and NP w/DiR. HeLa cells and A549 cells were treated with NP w/ DiR (blue line) or 
NP w/DiR/FA (red line) for (a) 0.5h and (b) 1h. After nanoparticle treatment, all cells 
were washed twice by PBS. The fluorescent intensity of cells was examined by flow 
cytometer combined with APC-Cy7 channel. 
 
(a) 
(b) 
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(3) folate competition experiment: 
     To further confirm the active targeting capability of our folate-functionalized 
nanoparticles, we pretreated HeLa and A549 cells with 1, 2, and 4 mM folate for 1h and 
repeated the same experiment. As we can see in Figure 10, HeLa cells showed folate-
dependent decreasing cell uptake of our folate-functionalized nanoparticles. In contrast, 
cell uptake behavior of A549 cells was almost the same no matter how much folate 
molecules we added beforehand. These results may be caused by the blocking of 
overexpressed folate receptors on HeLa cells. However, the deficient expression of folate 
receptors on A549 cells caused no difference of folate-functionalized nanoparticles cell 
uptake. All in all, these results confirm active targeting capability of our folate-
functionalized hybrid nanoparticles.  
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Figure 10: Flow cytometry results of HeLa and A549 cell uptake with folate pre-
treatment for 1h. Then, (a) HeLa and (b) A549 cells were treated with NP w/DiR/FA for 
1h. After nanoparticle treatment, all cells were washed twice by PBS. The fluorescent 
intensity of all cells was examined by flow cytometer combined with APC-Cy7 channel. 
 
 
 
 
 
(b) 
(a) 
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(4) Cell viability:  
     To make sure our DiR- or IR-1061-loaded hybrid nanoparticles have very little 
cytotoxicity, we use MTT assay to test the cell viability of HeLa and A549 cells treated 
with DiR- or IR-1061-loaded nanoparticles. In Figure 11, both cell lines were treated 
with DiR- or IR-1061-loaded nanoparticles. The cell viability of HeLa and A549 cells 
was over 90% even after they were treated 200 µg/mL DiR- or IR-1061-loaded 
nanoparticles for 4h. These results validate our DiR- or IR-1061-loaded nanoparticles 
have very little cytotoxicity. Since PLGA and PEG polymers were FDA approved and 
validated to be biocompatible, the biocompatibility of these materials gives rise to the 
minimal cytotoxicity of our DiR- or IR-1061-loaded hybrid nanoparticles.  
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Figure 11. Cell viability of HaLa and A549 cells treated with (a) DiR and (b)IR-
1061-loaded hybrid nanoparticles at different concentrations for 4h. 
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4. Release Profile 
     The release profile of IR-1061-loaded hybrid nanoparticles in PBS at pH 7.4, 6.6, 
5.7, and 4.5 was illustrated in Figure 12. In all testing groups, the amount of released IR-
1061 was increasing when time went on. Furthermore, the more acidic the environment, 
the more IR-1061 molecules were released. Again, this may be due to the positively 
charged nature of IR-1061 molecules. In more acidic environment, the extra protons 
could interact with the negatively charged PLGA core. So, the electrostatic interaction 
between IR-1061 and PLGA core was disturbed, which led to IR-1061 release. To 
confirm our hypothesis. The size, PDI, and zeta-potential of releasing samples were 
measured by DLS at 24h (Table 4). The size of all releasing nanoparticles had little 
change but the zeta-potential of zeta-potential become more positive in more acidic 
environment. The results further confirm our hypothesis about how IR-1061 molecules 
are released. However, the IR-1061-loaded nanoparticles released their IR-1061 
molecules over 60 % at 96h only in PBS at pH 4.5. At pH 5.7 and 6.6, the hybrid 
nanoparticles slightly released IR-1061 more than 50%. At pH 7.4, the nanoparticles 
barely released IR-1061 molecules over 40%. This may results from the hydrophobic 
interaction between IR-1061 molecules and PLGA core. Specifically, although the 
disturbance of electrostatic interaction between IR-1061 molecules and PLGA cores. IR-
1061 molecules still have some hydrophobic interactions between PLGA cores, which 
causes substantial release of IR-1061.     
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Figure 12: Release profile of IR-1061-loaded hybrid nanoparticles in PBS at pH 7.4, 
6.6, 5.7, and 4.5. 
 
Table 4. Characterization of releasing samples at 24h. 
sample Average size (nm) PDI zeta-potential (mV) 
NP w/IR-1061 136.6 0.102 -22.2±4.2 
NP release at pH 7.4 153.6 0.215 -16.8±4.2 
NP release at pH 6.6 149.6 0.207 -18.2±9.4 
NP release at pH 5.7 147.3 0.211 -14.8±1.3 
NP release at pH 4.5 141.7 0.171 -0.8±3.4 
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     However, we found that some aggregate appeared in our releasing samples when 
releasing time went up to 24h. Figure 13 shows the aggregate in our releasing samples at 
72h. More aggregate showed up in releasing samples in acidic environment, especially at 
pH 4.5. Combined with the release profile in Figure 12, we conclude that the released IR-
1061 molecules aggregate in aqueous environment due to their hydrophobicity. As a 
result, the greater amount of released IR-1061 molecules in PBS at pH 5.7 and 4.5 
severely agglomerated and cause pronounced aggregate in PBS.  
 
Figure 13: Releasing samples in pH 7.4, 6.6, 5.7, and 4.5 PBS at 72h. 
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5. Photoacoustic Imaging 
(1) Detection limit of IR-1061 in DMSO: 
 The photoacoustic imaging of free IR-1061 dissolved in DMSO was shown in 
Figure 14. As we can see, the higher concentration of IR-1061, the higher the 
corresponding photoacoustic intensity. We used Image J to quantify the pixel intensity 
and found that the IR-1061 concentration-dependent increasing tendency of 
photoacoustic intensity (Figure 15 (a)). Furthermore, the linear regression (Figure 15 (b)) 
illustrated remarkable linear fit (R2>0.95). Combined with the standard line and the mean 
of DMSO blank plus three standard deviation of DMSO blank, we obtained the detection 
limit of IR-1061 was 7.04 µM.   
Figure 14: Photoacoustic imaging of free IR-1061 at 200, 100, 50, 25, 12.5, 6.25, 
3.125 µM in DMSO. 
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Figure 15: Quantification of photoacoustic intensity from free IR-1061 at different 
concentrations in DMSO. (a) PA average intensity of IR-1061 at 200, 100, 50, 25, 12.5 
µM in DMSO. (b) Standard line of photoacoustic intensity against IR-1061 at 200, 100, 
50, 25, 12.5 µM in DMSO. 
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(2) IR-1061-loaded hybrid nanoparticles: 
     The photoacoustic imaging of IR-1061-loaded nanoparticles are illustrated in 
Figure 16. Combined with Table 5, it was obvious that the photoacoustic signals came 
from IR-1061 since PBS and nanoparticles without IR-1061 did not have signals in the 
image. However, the nanoparticles loaded with IR-1061 less than 50 µM also have no 
photoacoustic signals. When IR-1061 molecules were loaded into nanoparticles, it was 
highly likely that the locally high concentration of IR-1061 may quench photoacoustic 
signals of itself. As a result, the nanoparticles loaded with IR-1061 at 25 µM showed no 
photoacoustic signal even though the concentration of IR-1061 is much higher than the 
detection limit (7.04 µM). 
 
Figure 16: Photoacoustic imaging of IR-1061-loaded nanoparticles. The samples from 
left to right are 1: PBS, 2: NP w/IR-1061100 µM, 3: NP w/o IR-1061, 4: NP w/IR-1061 
50 µM, 5: NP w/IR-1061 50µM, 6: NP w/IR-1061 12.5 µM, 7: NP w/IR-1061 6.25 µM, 
and 8: NP w/IR-10613.125 µM. 
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Table 5: Photoacoustic imaging of IR-1061-loaded nanoparticle samples. 
index sample 
1  PBS 
2  NP w/IR-1061 100 µM 
3  NP w/o IR-1061 
4 NP w/IR-1061 50 µM 
5 NP w/IR-1061 25 µM 
6 NP w/IR-1061 12.5 µM 
7 NP w/IR-1061 6.25 µM 
8 NP w/IR-1061 3.125 µM 
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(3) Photoacoustic Imaging of Release Samples: 
     We measured the photoacoustic intensity of all releasing samples. Figure 17 
showed the photoacoustic imaging of IR-1061 released from our nanoparticles in PBS at 
different pH at 0.5h. The result corresponds to the release profile (Figure 12). As we 
expected, there were higher amount of IR-1061 released in PBS in more acidic 
environment. These higher amount of IR-1061 induced more thermos-elastic expansion 
effect and caused higher photoacoustic intensity in the imaging. 
 
 
 
Figure 17: Photoacoustic imaging of IR-1061 released from hybrid nanoparticles in 
PBS at pH 7.4, 6.6, 5.7, 4.5 at 0.5h. 
 
NP	  w/IR-­‐1061	  	  	  	  	  	  	  pH	  7.4	  	  	  	  	  	  	  pH	  6.6	  	  	  	  	  pH	  5.7	  	  	  	  	  	  	  pH	  4.5	  	  	  	  	  	  PBS 
3	  mm 
	   	   	  
	  
35 
	  
Discussion 
1.   Characterization of DiR- and IR-1061-loaded hybrid nanoparticles 
     In this study, we successfully developed DiR-loaded and IR-1061-loaded hybrid 
nanoparticles. The average size of DiR-loaded and IR-1061-loaded nanoparticles are 
around 200 nm and 130 nm, respectively, which is optimal for extravasation across 
premature and abnormal vasculature in tumor tissues22. So, our nanoparticles could 
passively accumulate in tumor tissues by enhanced permeability and retention (EPR) 
effect. It’s rather reasonable that the size of our DiR- and IR-1061-loaded hybrid 
nanoparticles are both larger than PLGA nanoparticles (45.7 nm) because the extra PEG 
hydrophilic shell enlarges the average size of the hollow hybrid nanoparticles. Also, the 
encapsulated DiR and IR-1061 molecules further make the average size of the hybrid 
nanoparticles even larger. Besides, both DiR-loaded and IR-1061-loaded nanoparticles 
obtain around 70% of dye loading efficiency. DiR molecules were encapsulated in PLGA 
hydrophobic core by hydrophobic interactions while IR-1061 molecules were loaded into 
nanoparticles by hydrophobic interactions and electrostatic interactions. The high dye 
loading efficiency may be due to lipid-polymer interface. The interface around PLGA 
polymer can prevent diffusion of hydrophobic dye molecules out of nanoparticles and 
enhance the dye loading. Plus, the pronounced blue shift (absorbance peak at 1074 nm to 
900 nm) absorbance spectrum occurred when IR-1061 molecules were loaded into 
nanoparticles. The blue shift may be due to the π-π stacking interactions between DiR 
and IR-1061 molecules when they aggregate in the PLGA hydrophobic core. This may 
change the electron resonance properties and ultimately result in blue shift of the 
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absorbance spectrum. This property made IR-1061 a potential candidate to combine with 
anticancer drugs and utilize in drug delivery.   
 
2.   Active targeting capability of DiR-loaded hybrid nanoparticles 
     To validate active targeting capability of our hybrid nanoparticles, we use anti-
folate receptor antibodies to stain A549, HeLa, Ov2008, and SKOV3 cells. After 
immune-staining, A549 and HeLa cells were selected as folate receptor negative and 
positive cell lines because of the 1. 1-fold and 7.1-fold expression of folate receptors on 
their cell membrane, respectively. We co-incubated A549 and HeLa cells with our folate-
functionalized nanoparticles loaded with DiR and used flow cytometer to track the cell 
uptake of our nanoparticles. It turned out that 95.8% of our folate-functionalized 
nanoparticles could be rapidly engulfed into HeLa cells in 0.5 h via receptor-mediated 
endocytosis. In contrast, A549 cells only nonspecifically engulfed 45.2% of our folate-
functionalized nanoparticles in 0.5 h. Furthermore, we used folate pre-treatment to further 
confirm the active targeting capability of our folate-functionalized nanoparticles. After 
folate pre-treatment, HeLa cells showed dose-dependent decrease cell uptake of our 
folate-functionalized nanoparticles while A549 cells had no difference of their cell 
uptake. The dose-dependent decrease cell uptake of folate-functionalized nanoparticles in 
HeLa cells results from blocking of folate receptors on their cell membrane. On the other 
hand, blockage of folate receptors had little effect to the originally folate receptor-
deficient A549 cells. As a result, we firmly validate the active targeting capability of our 
folate-functionalized nanoparticles. After passing through inter-endothelial junctions of 
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tumor vasculature, our nanoparticles can not only passively accumulate in tumor tissues 
but also be engulfed by tumor cells via folate receptor-mediated endocytosis. 
     
3.   Photoacoustic imaging and release profile of IR-1061-loaded hybrid 
nanoparticles  
     In photoacoustic imaging, we obtained the detection limit of IR-1061 in DMSO 
was 7.04 µM. However, when IR-1061 molecules were encapsulated into hybrid 
nanoparticles, it showed no photoacoustic signal even the IR-1061 was at 25 µM, which 
was 4 times higher than the detection limit. This may be due to the aggregation of IR-
1061 molecules in the PLGA core. When IR-1061 molecules aggregate, they couldn’t get 
irradiated efficiently to produce thermal expansion effect and acoustic wave, which 
ultimately results in weak photoacoustic signals. Then, our IR-1061-loaded nanoparticles 
were added to PBS at pH 7.4, 6.6, 5.7, and 4.5 to initiate the release experiment. We 
harvested the supernatant of each release sample at different time points. The supernatant 
samples were scanned by photoacoustic transducer. At all the time points, the more acidic 
the environment, the more IR-1061 get released. We speculated that the pH-responsive 
release profile stemmed from the positive charges on IR-1061 molecules. At lower pH, 
the protons disturb the electro-static interactions between negatively charged PLGA core 
and IR-1061 and lead to greater amount of IR-1061 release. The pH-responsive release 
profile was further validated by photoacoustic imaging. Similarly, the releasing samples 
in pH 4.5 and 5.7 obviously obtained stronger photoacoustic signals than in pH 6.6 and 
7.4.  Again, it’s due to the greater amount IR-1061 released in more acidic PBS. 
However, the greater amount of released IR-1061 also caused more aggregates in 
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aqueous solution when release time went up to 24h. This is mainly due to hydrophobic 
nature of IR-1061. Although the increase amount of IR-1061 molecules released leads to 
strong photoacoustic signals in the beginning, the photoacoustic signals decay in the long 
run. It’s due to the fact that IR-1061 molecules aggregate in PBS when they are released 
to some extent. In our long-term goal to track release profile of IR-1061-drug conjugates 
via photoacoustic imaging, we should chemically modify IR-1061 molecules and make 
more hydrophilic. Otherwise, the aggregation of IR-1061 would quench the 
photoacoustic signals in releasing samples and cause inaccurate quantification of released 
IR-1061 molecules.    
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Materials and Methods 
1. Preparation of DiR-loaded hybrid nanoparticles  
     The hybrid nanoparticles we used in this research studies were made by 
nanoprecipitation method21. Briefly, prepare 1 mg/mL lecithin/ DSPE-PEG-folate (1,2-
distearoyl-sn-glycero-3-phoshoethanolamine-N-carboxy(polyethylene glycol)5000-
folate) mixed lipid solution and 1mg/mL PLGA (poly(D,L-lactic-co-glycolic acid)) 
solution. Lecithin and DSPE-PEG-folate (molar ratio 85/15) were dissolved in 4% (v/v) 
ethanol and PLGA polymers were dissolved in acetonitrile solution. Then, the PLGA 
solution was added dropwise into mixed lipid solution under gentle stirring. After adding 
PLGA solution, the whole solution was vortexed for 3 min and further stirred for 2h. 
Then, we used Ultra-4 centrifugal filter (Millipore, Billerica, MA) with molecular weight 
cutoff of 10,000 Da to harvest the nanoparticles by centrifuging the nanoparticle solution 
at 4000×g for 15 min. To make DiR (Biotrium)-loaded hybrid nanoparticles, DiR with 
optimal dosage was added to PLGA acetonitrile solution before the nanoprecipitation 
process. The size (diameter, nm) and the surface charge (ζ potential, mV) were measured 
by quasi-elastic laser light scattering with a ZetaPALS dynamic light scattering detector 
(Brookhaven Instruments Corporation, Holsville, NY).  
 
2. Preparation of IR-1061-loaded hybrid nanoparticles 
     The hybrid nanoparticles we used in this research studies were made by 
nanoprecipitation method20. Briefly, prepare 1 mg/mL or 2 mg/mL lecithin/ DSPE-PEG-
folate (1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-carboxy(polyethylene 
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glycol)5000-folate) mixed lipid solution and 1mg/mL PLGA (poly(D,L-lactic-co-glycolic 
acid)) solution. Lecithin and DSPE-PEG-folate (molar ratio 85/15) were dissolved in 4% 
(v/v) ethanol and PLGA polymers were dissolved in DMSO (dimethyl sulfoxide) 
solution. Then, the PLGA solution was added dropwise into mixed lipid solution under 
sonication. After adding PLGA solution, the whole solution was further sonicated for 5 
min. Then, wash hybrid nanoparticles 5 times with an Amicon Ultra-4 centrifugal filter 
(Millipore, Billerica, MA) with molecular weight cutoff of 100,000 Da to remove the 
remaining DMSO solvent in the nanoparticle solution. To make DiR or IR-1061 loaded 
hybrid nanoparticles, DiR or IR-1061 with optimal dosage was added to PLGA DMSO 
solution before the nanoprecipitation process. The size (diameter, nm) and the surface 
charge (ζ potential, mV) were measured by quasi-elastic laser light scattering with a 
ZetaPALS dynamic light scattering detector (Brookhaven Instruments Corporation, 
Holsville, NY).  
 
3. Dye loading and release study 
     To obtain the dye loading efficiency, 1 mL nanoparticle solution was lyophilized. 
Then, use the equivalent amount of DMSO to destroy nanoparticles and get the 
encapsulated DiR or IR-1061 released. The absorbance of DiR (at 765 nm) and IR-1061 
(at 1074 nm) the solution was measured by plate reader or UV-VIS-NIR 
spectrophotometer. Combined with their standard line, we can calculate the amount of 
encapsulated DiR or IR-1061. Then, we can calculate the loading efficiency by using the 
following equation. 
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Loading Efficiency = !"#	  %&'()!	  '*	  #)+%,-(.%!#/	  /0#!"#	  %&'()!	  '*	  %//#/	  /0#	   ×100%  
In this study, we used IR-1061 loaded nanoparticles to do the release study. 
Briefly, 0.5 mL concentrated IR-161 loaded nanoparticles were harvested and added to 
9.5 mL PBS at pH 7.4, 6.6, 5.7, and 4.5. The starting concentration of IR-1061 in 
nanoparticles was 15 µM. Then, we split the releasing solution at different pH into 10 
microcentrifuge tubes (1 mL/ tube) and put them in 37 °C isothermal oven. All samples 
were kept rotating in isothermal oven via rotor to prevent precipitation of nanoparticles. 
Releasing samples were spun down (10,000×g, 20 min) at 0.5, 1, 2, 4, 8, 24, 48, 72, and 
96h. We collected the supernatant of each sample and measured the absorbance and 
photoacoustic intensity by UV-VIS-NIR spectrophotometer and Vivo LAZR scanner, 
respectively.    
 
4. Immunostaining of folate receptors 
     A549, HeLa, Ov2008, and SKOV3 cells were plated on 6-well tissue culture plate 
(250,000 cells/ well) and incubated for 24h. Remove the cell medium. Trypsinize cells 
and spin down cells at 1000 rpm for 5 min. Remove the supernatant and collect the cell 
pallets. Then, add 1 mL ice-cold PBS to resuspend the cells and start immunostaining by 
adding 3 µL primary antibodies. For control group, just add 3 µL of PBS instead of 
primary antibodies to compare the results. Then, incubate the cells for 1h on ice bath. 
After 1h incubation, remove the primary antibodies-containing cell medium and use PBS 
to wash cells 2 times. Then, resuspend the cells in ice-cold PBS.  After resuspension, add 
4 µL secondary antibodies to all cell samples including control group and incubate them 
on ice bath for another 1h. Finally, remove the antibodies-containing PBS, wash the cells 
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twice with ice-cold PBS, and resuspend the cells in ice-cold PBS. We use flow cytometer 
to examine the FITC signals in each cell line. 
 
5. Cell uptake 
     The cell models we used in this study were A549 and HeLa cells to validate the 
active targeting capability of our folate-functionalized hybrid nanoparticles. A549 is a 
small cell lung cancer cell line which has deficient folate receptor expression on its’ 
surface of cell membrane. In contrast, HeLa is a cervical cancer cell line which has folate 
receptor overexpression on the cell membrane. A549 and HeLa cells were plated on 6-
well tissue culture plate (250,000 cells/ well) and incubated for 24h. Remove the RPMI 
cell medium. Then, add DiR-loaded hybrid nanoparticles to cell medium and incubate 
with cells for 0.5 and 1h. After incubation, remove the nanoparticle-containing cell 
medium and use PBS to wash cells 2 times. After washing, add 1 mL trypsin to trypsinize 
cells for 5 min. Then, add 2 mL RPMI cell medium and spin down (1000 rpm, 5 min) 
cells. Aspirate the medium and add 1 mL methanol to fix the cells for 10 min. Again, spin 
down (1000 rpm, 5 min) the cells and wash the cells 2 times to remove remaining 
methanol. After washing, re-suspend the cells with 1 mL PBS and put the cell solutions 
in ice-bath. Use flow cytometer to measure the DiR intensity of all samples. To further 
confirm the active targeting capability of our folate-functionalized nanoparticles. We did 
the folate competition experiment. Briefly, we added RPMI medium containing 1, 2, 4 
mM folate to the wells for 1h prior to adding any DiR-loading nanoparticles. After folate 
pre-treatment, we followed the same process to examine the cell uptake of DiR-loaded 
nanoparticles. 
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6. Cell viability 
     A549 and HeLa cells were plated on 96-well plate (8000 cells/well) and 
incubated for 24h. Remove the cell medium and add 100 µL RPMI medium containing 
200, 100, 50, 25, 12.5 µg/mL IR-1061- loaded nanoparticles and 70% ethanol to the 
wells. After 4h, remove the medium or ethanol and add 100 µL 10% MTT reagent to 
treat the cells for another 4h. Then, remove the MTT reagents and add 100 µL DMSO to 
dissolve the purple crystals. Use plate reader to measure the absorbance at 570 nm. 
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Conclusion 
     In this study, we successfully developed nanoparticle-based imaging agents 
which can be applied to in vivo imaging and ovarian cancer diagnosis. The size DiR-
loaded and IR-1061-loaded nanoparticles are optimized for extravasation in tumor 
vasculature and able to passively accumulated in tumor tissues. The lipid-polymer 
interface in our hybrid nanoparticles promotes higher loading of DiR and IR-1061. The 
loading efficiency of these imaging agents could be as high as 70%. Moreover, our 
folate-functionalized nanoparticles with DiR could actively target to HeLa cells and be 
rapidly engulfed via receptor-mediated endocytosis in 0.5h. We even performed folate 
competition experiment to further validate the active targeting capability of our 
nanoparticles. Then, the release profile of IR-1061 loaded nanoparticles were examined. 
Obviously, it’s a substaintial release profile with pH-responsive release tendency. The 
release of IR-1061 can reach around 60% in pH 4.5 PBS at 96h. Nonethelss, the 
hydrophobicity of IR-1061 cause severe aggregation after 24h and quenching of 
photoacoustic signals. Hence, we need to chemically modified the IR-1061 molecules 
and make it more hydrophilic in the future so that we can utilize photoacoustic imaging 
to accurately quantify the release of IR-1061-drug conjugates. 
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